IMRX Immuneering Corp

$IMRX Bought another 1,000 I think I’m at about 14,000 shares. As my Italian friend used to say “What are you gonna do?!?” Spoken with thick accent of course. Cap

$IMRX Exploratory Phase 2a analysis of atebimetinib + modified gemcitabine/nab-paclitaxel (mGnP) found 84% of evaluable first-line pancreatic cancer patients had stable or increased weight at three months, roughly twice the rate observed in a published benchmark study.Patients with stable or increased weight at three months had significantly longer overall survival than those who lost weight (HR=3.13; p=0.049); median OS was not reached in the weight-stable/gain group after 15.2 months median follow-up.Analysis also found survival was comparable between patients achieving moderate (0-30%) and deeper (=30%) tumor-volume reductions, suggesting the presence of tumor shrinkage may be more important than its magnitude; median OS was not reached in either group.Findings build on previously reported 17.3-month median OS in 55 first-line pancreatic cancer patients treated with atebimetinib + mGnP; the combination is now being evaluated in the actively enrolling Phase 3 MAPKeeper 301 trial.

$IMRX someone must know that you're such a clown, the entire biotech is down 20%...wake up pal!!!

$IMRX bought a nice chunk today. Let’s see if we get a run up before they release data at the end of this month

$IMRX I'm going to close my eyes now, and hope that when I awake, this jump will still be there. I've seen this game before. Keeping my fingers crossed.

$IMRX upper $3’s and low $4’s has been a great place to buy this year. Hopefully we will see a bounce as we get closer to the October presentation

$IMRX slow end to recruiting...when it changes to "Active, not recruiting" the stock will get a boost. RVMD was from 17-60 for 5 years before Merck offered a buyout in Jan 2026. Skyrocketed then collapsed a little before FDA approval skyrocketed it to all time highs. IMRX needs confirmation from an ** RCT study ** (not necessarily FDA approval but interim data , hopefully mid 2027) or a buyout offer for it to skyrocket too. It still has all the makings of wealth generating stock in the future.

$IMRX getting in now is at a 50% discount to what Sanofi paid for during that $25 mil private placement

$IMRX State Street Corp reports 273.15% increase in ownership of IMRX / Immuneering Corporation On September 22, 2026 - State Street Corp filed a 13F-HR/A form disclosing ownership of 1,001,995 shares of Immuneering Corporation (US:IMRX) valued at $4,999,955 USD as of June 30, 2026. The entity filed a previous 13F-HR on May 15, 2026 disclosing 268,520 shares of Immuneering Corporation. This represents a change in shares of 273.15% during the quarter. The current value of the position is $4,348,658 USD.

$IMRX Chat is valuing this based on probablitues of success. It gives IMRX a 60% probability of success and $150M failure value: (60% × $1.5B) + (40% × $150M) = $960M Divided by 75M diluted shares = approximately $12.80/share. I'll take thst for mow.

$IMRX Down & down & down she goes. Wonderful. To the monsters who do this, I hope you will need this drug one day, bastards.

$IMRX At this price the company should start buying back shares to sell later above $9. They absolutely have to counter this short attack.

$IMRX 15-25 days to cover short interest at current volumes. any news and this could pop.. cant believe we are trading sub 4.

$IMRX Good luck to $RVMD $VSTM and other RAS inhibitors - especially with some recent concerns on $RVMD’s efficacy - but hopefully these inhibitors help PDAC patients. This is all occurring at the top of the MAPK pathway. The great news is - $IMRX’s Atebi is an MEK inhibitor working downstream on the MAPK pathway. Should $IMRX’s current Phase 3 trial (n=510) - replicate its amazing Phase 2 data on 55 patients (mOS 17.3mos - excellent tolerability) - then patients will potentially have a multitude of options. However the RAS protocol plays out - downstream Atebi would be a viable option - either - on its own (combo with chemo) - or together with the upstream RAS inhibitor. The risk/reward of $IMRX is incredible Market Caps $IMRX 250M $RVMD 41B I am not a scientist or a doctor - would love for someone to support or counter above thought process

$IMRX A full year of nothingness. Great news doesn't matter anymore. It is so controlled IMO. How can this only move sideways or down? I see stocks with 1 million caps jump every day and hold at $4. This company wants to cure PC, but it will give you a heart attack on the way. So infuriating.

$IMRX • Exploratory Phase 2a analysis of atebimetinib + modified gemcitabine/nab-paclitaxel (mGnP) found 84% of evaluable first-line pancreatic cancer patients had stable or increased weight at three months, roughly twice the rate observed in a published benchmark study. • Patients with stable or increased weight at three months had significantly longer overall survival than those who lost weight (HR=3.13; p=0.049); median OS was not reached in the weight-stable/gain group after 15.2 months median follow-up. • survival was comparable between patients achieving moderate (0-30%) and deeper (=30%) tumor-volume reductions, suggesting the presence of tumor shrinkage may be more important than its magnitude; median OS was not reached in either group. • Findings build on previously reported 17.3-month median OS in 55 first-line pancreatic cancer patients treated with atebimetinib + mGnP; the combination is now being evaluated in the actively enrolling P hase 3 MAPKeeper 301 trial.

$IMRX (Atebi) and $RVMD (Daraxon) both in Phase 3 for 1L Daraxon is already approved for 2L Assume both have comparable positive outcomes Doesn’t the scenario of Atebi in 1L followed by Daraxon in 2L make more sense than: Daraxon in 1L and no 2L option

$IMRX well, I didn’t expect to see it get this low! I guess I started buying a bit too early on this one

$IMRX AACR Conference on Pancreatic Cancer: New Frontiers in Biology and Therapeutic Development September 25-28, 2026 Hilton Bayfront San Diego San Diego, California Conference Cochairs Andrew J. Aguirre, Dana-Farber Cancer Institute, Boston, Massachusetts Florencia McAllister, The University of Texas MD Anderson Cancer Center, Houston, Texas Kenneth P. Olive, Herbert Irving Comprehensive Cancer Center, New York, New York Eileen O’Reilly, Memorial Sloan Kettering Cancer Center, New York, New York **** Diane M. Simeone, University of California, San Diego, California Colin D. Weekes, Massachusetts General Hospital, Boston, Massachusetts New York, New York, United States, 10065 RecruitingMemorial Sloan Kettering Cancer Center Contact : Eileen O'Reilly, MD **** Memorial Sloan Kettering Cancer Center (MSK) has been ranked the number one hospital in the world for oncology in Newsweek's World's Best Specialized Hospitals 2027 ranking.

$IMRX It appears institutions would rather wait for positive phase 3 results and buy at a higher price than buy now and be disappointed by a negative outcome.